OWINGS MILLS, Md.--(BUSINESS WIRE)--Univec, Inc. (OTC: UNVC) a specialty pharmaceutical company, announces it has completed the R&D for its Nicotine Replacement Patch. Univec anticipates product production by the end of next quarter. Univec’s Transdermal Delivery system enhances bioavailability, minimizes pharmaco-kinetic peaks, improves tolerability and dosing, increases patient compliance, and continuous delivery.
